REIMAGINING T-CELL
ENGINEERING
ENGINEERING
to unlock the promise of immunotherapy
A treatment approach
with the potential to transform patient outcomes
Vittoria Biotherapeutics is a clinical-stage company with a novel platform technology, Senza5, that powers a pipeline of highly differentiated immunotherapies designed to address unmet clinical needs in oncology and immunology.
NEXT-GENERATION, ENABLED-AUTOLOGOUS CAR T-CELL THERAPIES
Our therapies are being developed with a goal of improving efficacy, safety, and accessibility.
Proprietary
SENZA5™ platform
technology
Unprecedented utility and superior potency are achieved by CD5 signaling modulation and a novel 5-day manufacturing process.
CLINICAL TRIAL
RECRUITING NOW
Our VIPER-101 Phase 1 trial for the treatment of T-cell lymphoma is currently enrolling participants (NCT06420089).
News
DECEMBER 12, 2024
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
DECEMBER 09, 2024
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies
NOVEMBER 25, 2024
Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting